Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Xeloda as Adjuvant Monotherapy in Colon Cancer
NCT00502671Phase 4Completed
- Sponsor
- Roche
- Start
- Jul 2007
- Primary completion
- Mar 2012
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of capecitabine in colon cancer, sponsored by Roche. Started Jul 2007; status: completed.
02
Drugs
capecitabine
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT00502671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00502671.